(VIANEWS) – Marathon (MARA), MACOM Technology Solutions Holdings (MTSI), Federal Signal Corporation (FSS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Marathon (MARA)
74.9% sales growth and 31.74% return on equity
Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the bitcoin ecosystem in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.
Earnings Per Share
As for profitability, Marathon has a trailing twelve months EPS of $1.06.
PE Ratio
Marathon has a trailing twelve months price to earnings ratio of 15.2. Meaning, the purchaser of the share is investing $15.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.74%.
Previous days news about Marathon(MARA)
- According to Zacks on Tuesday, 28 May, "Investors interested in theenergysector may look at a couple of better-ranked stocks like Marathon PetroleumCorporation (MPC Quick QuoteMPC – Free Report) and SM Energy Company (SM Quick QuoteSM – Free Report) , both carrying a Zacks Rank #1 (Strong Buy) at present. "
- According to Zacks on Tuesday, 28 May, "SM Energy and Marathon Petroleum sport a Zacks Rank #1 (Strong Buy), and Eni carries a Zacks Rank #2 at present. "
- According to Zacks on Wednesday, 29 May, "Some better-ranked players in theenergysector are Marathon PetroleumCorporation (MPC Quick QuoteMPC – Free Report) , SM Energy Company (SM Quick QuoteSM – Free Report) and Sunoco LP(SUN Quick QuoteSUN – Free Report) . ", "While Marathon Petroleum and SM Energy currently sport a Zacks Rank #1 (Strong Buy) each, Sunoco carries a Zacks Rank #2 (Buy). "
- According to Zacks on Wednesday, 29 May, "Considering this optimistic picture, we recommend Oil/Energy investors to accumulate stocks like SM Energy Company (SM Quick QuoteSM – Free Report) , Marathon Petroleum (MPC Quick QuoteMPC – Free Report) and ProPetro Holding (PUMP Quick QuotePUMP – Free Report) . ", "SM Energy and Marathon Petroleum currently sport a Zacks Rank #1 (Strong Buy) each, while ProPetro carries a Zacks Rank #2 (Buy)."
2. MACOM Technology Solutions Holdings (MTSI)
32.2% sales growth and 6.58% return on equity
MACOM Technology Solutions Holdings, Inc., together with its subsidiaries, designs and manufactures analog semiconductor solutions for use in wireless and wireline applications across the radio frequency (RF), microwave, millimeter wave, and lightwave spectrum in the United States, China, the Asia Pacific, and internationally. The company offers a portfolio of standard and custom devices, including integrated circuits, multi-chip modules, diodes, amplifiers, switches and switch limiters, passive and active components, and subsystems. Its semiconductor products are electronic components that are incorporated in electronic systems, such as wireless basestations, high capacity optical networks, radar, and medical systems and test and measurement. The company serves various markets comprising telecommunication that includes carrier infrastructure, which comprise long-haul/metro, 5G, and fiber-to-the-X/passive optical network; data centres; and industrial and defense, including military and commercial radar, RF jammers, electronic countermeasures, and communication data links, as well as multi-market applications, such as industrial, medical, test and measurement, and scientific applications. It sells its products through direct sales force, applications engineering staff, independent sales representatives, resellers, and distributors. The company was founded in 1950 and is headquartered in Lowell, Massachusetts.
Earnings Per Share
As for profitability, MACOM Technology Solutions Holdings has a trailing twelve months EPS of $0.89.
PE Ratio
MACOM Technology Solutions Holdings has a trailing twelve months price to earnings ratio of 113.31. Meaning, the purchaser of the share is investing $113.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.58%.
3. Federal Signal Corporation (FSS)
8.9% sales growth and 18.85% return on equity
Federal Signal Corporation, together with its subsidiaries, designs, manufactures, and supplies a suite of products and integrated solutions for municipal, governmental, industrial, and commercial customers in the United States, Canada, Europe, and internationally. It operates through Environmental Solutions Group, and Safety and Security Systems Group. The Environmental Solutions Group segment offers a range of street sweepers, safe-digging trucks ,sewer cleaners, industrial vacuum loaders, vacuum, and hydro-excavation trucks; road-marking, line-removal and waterblasting equipment, dump truck bodies, trailers, and metal extraction support equipment under the Elgin, Vactor, Guzzler, TRUVAC, Westech, Jetstream, Mark Rite Lines, Ox Bodies, Crysteel, J-Craft, Duraclass, Rugby, Travis, OSW, NTE, WTB, Ground Force, Bucks, and Switch-N-Go brand names. It also offers refuse and recycling collection vehicles, camera systems, ice resurfacing equipment, and snow-removal equipment, as well as safety, and security systems. In addition, this segment engages in the sale of parts, service and repair, equipment rental, and training activities. The Safety and Security Systems Group segment provides systems and products for community alerting, emergency vehicles, first responder interoperable communications, and industrial communications. Its products include vehicle lightbars and sirens, industrial signaling equipment, public warning systems, general alarm systems, and public address systems. This segment sells its products under the Federal Signal, Federal Signal VAMA, and Victor brand names. The company sells its products through wholesaler, distributor, independent manufacturer representative, original equipment manufacturer, and direct sales force, as well as independent foreign distributor. Federal Signal Corporation was founded in 1901 and is headquartered in Oak Brook, Illinois.
Earnings Per Share
As for profitability, Federal Signal Corporation has a trailing twelve months EPS of $2.95.
PE Ratio
Federal Signal Corporation has a trailing twelve months price to earnings ratio of 29.12. Meaning, the purchaser of the share is investing $29.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.85%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 25.4% and 11.3%, respectively.
4. Assurant (AIZ)
8% sales growth and 16.43% return on equity
Assurant, Inc., together with its subsidiaries, provides lifestyle and housing solutions that support, protect, and connect consumer purchases in North America, Latin America, Europe, and the Asia Pacific. The company operates through three segments: Global Lifestyle, Global Housing, and Global Preneed. The Global Lifestyle segment provides mobile device protection products and services, and extended service contracts for consumer electronics and appliances, as well as assistance services; vehicle protection and related services; and credit and other insurance services. The Global Housing segment offers lender-placed homeowners insurance, manufactured housing, and flood insurance; and renters insurance and related products, as well as voluntary manufactured housing insurance, homeowners insurance, and other specialty products. The Global Preneed segment provides pre-funded funeral insurance, final need insurance, and related services. The company was formerly known as Fortis, Inc. and changed its name to Assurant, Inc. in February 2004. Assurant, Inc. was founded in 1892 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Assurant has a trailing twelve months EPS of $14.3.
PE Ratio
Assurant has a trailing twelve months price to earnings ratio of 11.82. Meaning, the purchaser of the share is investing $11.82 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.43%.
Sales Growth
Assurant’s sales growth is 5.9% for the current quarter and 8% for the next.
Volume
Today’s last reported volume for Assurant is 353821 which is 6.95% above its average volume of 330809.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9%, now sitting on 11.37B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 2.1% and a drop 23.1% for the next.
5. ICON plc (ICLR)
6.5% sales growth and 7.55% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $8.24.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 38.33. Meaning, the purchaser of the share is investing $38.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.55%.
6. Regeneron Pharmaceuticals (REGN)
5.6% sales growth and 15.28% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $34.78.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.01. Meaning, the purchaser of the share is investing $26.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.28%.
Yearly Top and Bottom Value
Regeneron Pharmaceuticals’s stock is valued at $904.70 at 16:22 EST, below its 52-week high of $998.33 and way higher than its 52-week low of $684.81.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.5%, now sitting on 13.1B for the twelve trailing months.
Volume
Today’s last reported volume for Regeneron Pharmaceuticals is 518284 which is 9.88% above its average volume of 471642.
Moving Average
Regeneron Pharmaceuticals’s worth is under its 50-day moving average of $944.85 and higher than its 200-day moving average of $885.95.
